Cyclopharm Limited (ASX:CYC)

Market Cap	88.05M -59.0%
Revenue (ttm)	32.33M +17.2%
Net Income	-17.22M
EPS	-0.16
Shares Out	120.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,457
Average Volume	142,029
Open	0.7500
Previous Close	0.7400
Day's Range	0.7300 - 0.7500
52-Week Range	0.5600 - 1.5500
Beta	0.80
RSI	33.85
Earnings Date	Feb 24, 2026

About Cyclopharm

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1986
• Employees: 97
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CYC

Financial Performance

In 2025, Cyclopharm's revenue was 32.33 million, an increase of 17.24% compared to the previous year's 27.57 million. Losses were -17.22 million, 30.5% more than in 2024.